August 2018—EliTechGroup and R-Biopharm announced an agreement in which the two companies will develop, produce, and market real-time PCR reagents.
“We are very pleased to have won R-Biopharm as a partner to expand our molecular diagnostics portfolio,” Christoph Gauer, CEO of EliTechGroup, said in a statement. “This collaboration will contribute to complete the menu of our sample-to-result system Elite InGenius.”
EliTech aims to increase the number of its CE-IVD assays from 23 to 33 by the end of 2018.
EliTechGroup, +39 (0)2 48 40 35 42